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wrong.
The novelty of this study lies in the exploration of the added potential of performing a PET/CT derived biodistribution/dosimetry in humans for a mAb labelled with a positron emitter. The advantage of the associated (lowdose) computed tomography (CT) scan is more robust organ delineation. In addition, use of a CT defined volume of interest (VOI) of the lumbar vertebrae may allow for noninvasive quantification of RM activity concentrations. The aim of this study was to assess biodistribution and radiation dosimetry of 89 Zr-cetuximab in humans, with a special emphasis on a comparison of image and plasma based RM dose estimation approaches.
Materials and methods

Imaging protocol
Seven patients (4 men, 3 women) with histopathologically confirmed advanced kRas wild-type colorectal cancer (Table 4 .1) received 36.9 ± 0.8 MBq of 89 Zr-cetuximab within 2 h after administration of the first therapeutic dose of 500 mg⋅m −2 of cetuximab. PET/CT scans (Gemini TF-64; Philips Healthcare) and blood samples were obtained at 1, 24, 48, 94, and 144 h after injection (10) . PET data were normalized; corrected for decay, randoms, dead time, scatter and attenuation; and reconstructed using a time-of-flight list-mode ordered-subsets expectation maximization reconstruction method with a matrix size of 144 × 144 and a voxel size of 4 × 4 × 4 mm 3 . In addition, for each time point, a 50 mAs low dose CT scan was acquired for attenuation correction purposes. Corresponding CT images were reconstructed with an image matrix size of 512 × 512 and a voxel size of 1.17 × 1.17 × 5 mm 3 . For the present analysis, all 5 CT scans for each patient were re-binned into a 4 × 4 × 4 mm 3 voxel size to map CT VOIs onto the PET images. The study was approved by the Medical Ethics Committee of the VU University Medical Centre, and all patients signed a written informed consent form before the inclusion.
Organ dosimetry
The activity for each organ that was visible in all PET scans (liver, lungs, kidneys, spleen, and RM) was determined using the mean activity concentration in VOIs using in-house developed software. VOIs were independently drawn on all 5 CT scans for each patient and subsequently mapped onto the respective PET scans. Total organ activities were derived using standard organ masses as reported by Stabin et al. (11) . The cumulated activity was calculated as the area under the curve of the organ time-activity data approximated by the trapezoidal rule and assuming only physical decay after the last measurement. Next, the residence time was derived by dividing the cumulated activity by the total injected activity. The residence time in the remainder of the body was calculated as the maximum residence time (based on physical decay only) minus the sum of residence time of source organs (an organ was designated as source organ when uptake was visible), assuming no excretion during the time course of the scans. Although the effective total residence time could also be derived from a whole body VOI (on average 35% lower values), this approach was not followed to obtain conservative estimates of the effective dose. Individual residence times were scaled with the mass ratio of the patient to reference man/woman before being used as input in OLINDA/EXM 1.1. This software was used for calculation of organ absorbed doses and effective dose (11) .To derive a simplified dosimetry protocol with 3 time points, all possible combinations were tested for the ability to estimate organs absorbed doses and effective doses as accurate as possible.
RM dose estimation methods
Blood-based method
Conventionally, the blood based approach assumes that plasma activity concentration is equal to the extracellular fluid activity concentration in the marrow space and, therefore, that RMPR is constant, equal to the fraction of RM composed of extracellular fluid (RMECFF) (4) . In this method, a fixed, time-independent RMPR value of 0.19 is used. In Table 4 .2, a parameter overview can be found. Plasma samples were counted in a Wallac 1470 well counter (Perkin Elmer Lifescience) and conversion of the derived counts per minute to disintegration per minute was done (a description of the methodology of cross calibration between the PET scanner and the well counter can be found in Greuter et al. (12) ). The total cumulated activity concentration in the RM is given by: 
or alternatively the cumulated activity can be written as:
The RM mass can be approximated through the standard adult and patient specific whole body mass:
where
and m W B−patient correspond to the standard adult mass for RM (men: 1.12 kg, women: 1.30 kg), whole body (m: 73.7 kg, f: 58.0 kg) (11) , and the patient specific whole body mass, respectively (See Table 4 .2). The total RM absorbed dose can be divided into 2 contributions, the self RM dose-which represents the dose from the marrow spaces-and the cross RM dose-which represents the dose from the remaining tissues of the body (13, 14) . This can be expressed by the following equations:
The full expressions of self dose and cross dose contribution to the RM can be obtained by substituting Equations 4.2, 4.3 and 4.4 into 4.6. By introducing a mass scaling for the S factors in Equation 4.6, the m W B−patient terms cancel out and a patient mass independent term remains, whereas the final cross RM dose term will be patient mass dependent. Calculations and full expression of the formulas can be found in the Appendix.
Manual VOI delineation method
In immunoPET studies, a second approach to determine [Ã RM ] is by delineating VOIs in each of the 5 (L1-L5) segments of the lumbar vertebrae (LV) on CT slices (Figure 4 .1). Each VOI had a spheric shape with a volume of 6 mL, providing a total volume of 30 mL for all 5 segments. Subsequently, all 5 VOIs were transferred to the PET images, and the mean activity concentration was calculated. The effect of using smaller or larger volumes in estimating mean activity concentration was also investigated. The LV consists of compact bone, trabecular bone, and marrow space elements-that is, red and yellow marrow, extracellular fluid, and vasculature. Assuming that there is no specific binding of the radiolabelled antibody cetuximab to trabecular bone, it follows that the trabecular bone activity concentration should be zero. Thus, a correction factor was applied for the presence of trabecular bone in the LV segments. To this end, the RM activity concentration was scaled based on the volume of the LV composed of trabecular bone (f tb ;men, 0.135; women, 0.148) (15) , thus a multiplicative correction factor 1/1-f tb was applied. This approach does not assume a constant RMPR over time as it is an image derived method. Lu, only the self dose component of the overall RM dose should be taken into account. Relative change in self RM dose between LV based and plasma based approaches was 21% (whereas in total RM dose this difference was diluted due to the cross dose contribution, and therefore, the average relative change in total dose was only 6%) (Table 4. 3). The contribution of cumulated activity before the first and after the last scan as compared with the total RM cumulated activity was 16% ± 2% and 27% ± 4% for plasma and LV based methods, respectively. In addition, across all patients, the self RM dose percentage contribution to the total RM dose varied from 18% to 35%, whereas the whole body to blood cumulated activity ratio varied from 3.4 to 1.8.
Results
The organ average uptake for liver, lungs, kidneys, spleen, and RM is shown in Figure 4 .6. The highest average absorbed dose was observed in the liver with 2.60 ± 0.78 0.06 mGy⋅MBq −1 , followed by the kidneys (1.04 ± 0.24 mGy⋅MBq −1 ), spleen (0.89 ± 0.22 mGy⋅MBq −1 ), lungs (0.66 ± 0.17 mGy⋅MBq −1 ), and RM (0.51 ± 0.06 mGy⋅MBq −1 ). The effective dose was calculated to be 0.61 ± 0.09 mSv⋅MBq −1 . All possible 3 time-point combinations were tested in estimating organ absorbed doses and effective doses. The 1h-48h-144h and the 48h-72h-144h protocols showed the smallest (<4%) and the largest (∼20%) discrepancies, respectively, when compared with the 5 time-point dosimetry protocol (Table 4.4). Table 4 .5 shows organ effective half-lives of 89 Zr-cetuximab for 1-to 72-h and 72-to 144-h time intervals. Whole body effective half-life was 70 ± 6 h for the whole imaging range. 
Discussion
This study assessed PET/CT based biodistribution and dosimetry of 89 Zrcetuximab for all organs with positive PET uptake. In addition, an image based approach for estimating the RM absorbed dose in 89 Zr PET/CT studies was compared with the conventional plasma based approach. While 18 F-FDG is a metabolic tracer that targets tumours in a nonspecific manner, radiolabelled mAbs target a specific tumour cell surface marker. That said, immunoPET can give insight on tumour targeting and on the amount of the mAb accumulated in the tumour, offering the opportunity to select those patients who will benefit from mAb-based therapy and allowing treatment planning to be tailored to the needs of each patient. More information on the potential added value of immunoPET in the clinical setting is presented by Wu (16) .
The present study showed a nonconstant RMPR over time for 89 Zrcetuximab. Hindorf et al. (6) (17), who demonstrated an elevated bone uptake of 5.70 ± 3.00 %ID⋅g −1 at 120 h post-injection. In contrast, the present findings showed a constant RM uptake over time, which could be due to catabolism of cetuximab in the liver. Then the associated 89 Zr-containing metabolites re-enter the bloodstream and they redistribute in the bone marrow. Therefore, the increasing RMPR could be explained, at least in part, by the relative rapid washout of 89 Zr-cetuximab from the bloodstream in combination with the constant RM uptake. No foci of high activity were detected in bone sites.
The contribution of extrapolations in the cumulated activity before the first and after the last scan was below 20% as recommended by the dosimetry guidelines of European Association of Nuclear Medicine (18) . In addition, the small interpatient variation of the extrapolations (data not shown) implies that the uncertainty due to extrapolations is comparable between patients. Although the whole body to blood cumulated activity ratio decreased, the self RM dose percentage contribution to the total RM dose increased, thus making any variations in parameters related to self RM dose, such as HCT and RMECFF, more important.
The estimation of self RM dose as determined with the LV based approach yielded, on average, 21% higher values than those obtained with the plasma based approach. This is due to the constant RMPR (0.19) used in the plasma based approach. The present findings suggest an increasing RMPR, thus making the latter approach inappropriate. In other words, the relative faster washout of 89 Zr-cetuximab from the plasma component, compared with the constant uptake in the RM, suggests that the plasma based approach may not provide for an accurate estimation of RM absorbed doses. The total RM doses based on plasma and LV approaches were within 6% of each other. However, for therapeutic analogues with no or little emissions of long range photons (depending on their energy and half-life) only the self RM dose term is relevant.
The absorbed dose estimates in the present study are in line (within xii 20% for all organs except liver) with previous 89 Zr-labelled studies. Rizvi et al. (2) reported that, for 89 Zr-ibritumomab tiuxetan, the liver was the organ with the highest absorbed dose (1.36 ± 0.58 mGy⋅MBq −1 ), followed by the spleen (1.04 ± 0. 16 89 Zr-cetuximab is used only for diagnostic purposes, and therefore the effective dose was presented. But in the setting of radioimmunotherapy the dose on a tumour or the RM should be presented as absorbed dose as well. Because no tumour data are discussed in this article, only RM absorbed dose data have been reported. With regards to effective half-lives, only 1 immunoPET study reports on 89 Zr effective half-lives and more specifically in whole body biological clearance (20) . This was found to be 219 h on average, and it can be translated to 58 h on the whole body effective half-life. This figure is somewhat comparable to the 70 h seen in the current study. We split the image data points into 2 time intervals in order to gain insight of organ kinetics over time. With regards to the simplified 3 time-point dosimetry protocol, the first time-point (1 h) is of importance, because the use of it will lead to more accurate absorbed dose estimations than when using the 24 h scan. In addition, 89 Zr labelled mAbs exhibit slow kinetics; thus, targeting of specific organs or tumours will occur in late timepoints, making the 144 h time-point essential in a simplified protocol. The present study suggests that a simplified 3 time-point dosimetry approach may be used for organ absorbed dose estimation as an alternative to the reference approach, because it yielded similar results (within ∼4%). This will reduce the total scanning time, avoiding unnecessary discomfort and additional radiation burden (due to additional low-dose CT scans) to the patient and without compromising accuracy in dose estimation.
There are technical factors that may hamper accurate quantification of RM activity concentration and thus absorbed dose estimation. From a technical point of view, partial-volume effect might have resulted in underestimation of RM activity concentrations. On the basis of 89 Zr phantom studies (21) , the activity concentration of a 2.5 cm sphere surrounded by a homogeneous background can be underestimated by as much as 20%. Nevertheless, the present observation of a nonconstant (increasing) BMto-background ratio as function of time indicates that partial volume corrections based on a fixed factor taken from phantom studies (with sphereto-background ratio of 10) would provide misleading results. Schwartz et al. (5) used recovery coefficients for partial volume correction derived from phantom studies. Unfortunately, there was no report on how the BM-tobackground ratio behaved over time, because a nonconstant ratio would require a time-varying partial volume correction. Notably, the current study showed small deviations in AC RM while varying the VOIs, indicating a minimal impact of the partial-volume effect. In addition, the 6 mL VOIs were employed on the LV segments such that a distance of at least 1 cm ( 2 scanner spatial resolution) from the outer LV bone was ensured. In any case, even if partial-volume corrections were applied, it would only increase the dissociation of RM dose estimation between image and plasma based approaches.
Conclusion
Total RM dose estimates derived from plasma and image based approaches are equal within 6%. For dosimetry purposes in immunoPET this would be acceptable. Nevertheless, an image based approach, using manual delineation of the LV, is preferred for determining RM dose estimates, because it accounts for a non-constant RMPR. The liver showed the highest absorbed dose amongst all organs, and the effective dose was 0.61 ± 0.09 mSv⋅MBq −1 . A simplified approach using 3 time points appears to be feasible, reducing logistical costs and scanning time required. 
4.9
Final expressions for both self dose and cross dose to RM are obtained by substituting equations 4.2, 4.8 and 4.9 into 4.7: 
